Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) International — Reported Sales Growth (%) (%)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, Q3 2026
13.6%
Period ended Sep 30, 2026
Change on a year earlier
-11.3 pts
24.9% in Q3 2025
History
35 quarters
Since Q1 2018
Sources
35
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) International — Reported Sales Growth (%) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 13.6% | -11.3 pts | SEC Filing (0001628280-26-066601) ↗ |
| Q2 2026 | Jun 30, 2026 | 14.7% | -5.7 pts | SEC Filing (0001628280-26-048377) ↗ |
| Q1 2026 | Mar 31, 2026 | 27.2% | +10.9 pts | SEC Filing (0001628280-26-025365) ↗ |
| Q4 2025 | Dec 31, 2025 | 23.8% | -0.1 pts | SEC Filing (0001628280-26-002982) ↗ |
| Q3 2025 | Sep 30, 2025 | 24.9% | +7.1 pts | SEC Filing (0001628280-25-045049) ↗ |
| Q2 2025 | Jun 30, 2025 | 20.4% | -1.3 pts | SEC Filing (0001628280-25-035135) ↗ |
| Q1 2025 | Mar 31, 2025 | 16.3% | +6.5 pts | SEC Filing (0001628280-25-017924) ↗ |
| Q4 2024 | Dec 31, 2024 | 23.9% | +13.7 pts | SEC Filing (0001628280-25-002092) ↗ |
| Q3 2024 | Sep 30, 2024 | 17.8% | +10.4 pts | SEC Filing (0001628280-24-042893) ↗ |
| Q2 2024 | Jun 30, 2024 | 21.7% | +16.6 pts | SEC Filing (0001628280-24-032182) ↗ |
| Q1 2024 | Mar 31, 2024 | 9.8% | -3.7 pts | SEC Filing (0001628280-24-016497) ↗ |
| Q4 2023 | Dec 31, 2023 | 10.2% | +13.3 pts | SEC Filing (0001628280-24-002009) ↗ |
| Q3 2023 | Sep 30, 2023 | 7.4% | +18.5 pts | SEC Filing (0001628280-23-034544) ↗ |
| Q2 2023 | Jun 30, 2023 | 5.1% | +13.8 pts | SEC Filing (0001628280-23-025156) ↗ |
| Q1 2023 | Mar 31, 2023 | 13.5% | +23.0 pts | SEC Filing (0001628280-23-012020) ↗ |
| Q4 2022 | Dec 31, 2022 | -3.1% | -0.9 pts | SEC Filing (0001628280-23-001516) ↗ |
| Q3 2022 | Sep 30, 2022 | -11.1% | -24.9 pts | SEC Filing (0001628280-22-026588) ↗ |
| Q2 2022 | Jun 30, 2022 | -8.7% | -119.1 pts | SEC Filing (0001104659-22-081006) ↗ |
| Q1 2022 | Mar 31, 2022 | -9.5% | -8.1 pts | SEC Filing (0001104659-22-047560) ↗ |
| Q4 2021 | Dec 31, 2021 | -2.2% | +10.5 pts | SEC Filing (0001104659-22-007648) ↗ |
| Q3 2021 | Sep 30, 2021 | 13.8% | +21.5 pts | SEC Filing (0001104659-21-127874) ↗ |
| Q2 2021 | Jun 30, 2021 | 110.4% | +162.4 pts | SEC Filing (0001104659-21-094680) ↗ |
| Q1 2021 | Mar 31, 2021 | -1.4% | +1.3 pts | SEC Filing (0001104659-21-052205) ↗ |
| Q4 2020 | Dec 31, 2020 | -12.7% | -27.3 pts | SEC Filing (0001104659-21-007942) ↗ |
| Q3 2020 | Sep 30, 2020 | -7.7% | -4.2 pts | SEC Filing (0001104659-20-116611) ↗ |
| Q2 2020 | Jun 30, 2020 | -52.0% | -41.6 pts | SEC Filing (0001104659-20-083929) ↗ |
| Q1 2020 | Mar 31, 2020 | -2.7% | +3.4 pts | SEC Filing (0001104659-20-047187) ↗ |
| Q4 2019 | Dec 31, 2019 | 14.6% | +21.3 pts | SEC Filing (0001104659-20-005717) ↗ |
| Q3 2019 | Sep 30, 2019 | -3.5% | +2.0 pts | SEC Filing (0001104659-19-054283) ↗ |
| Q2 2019 | Jun 30, 2019 | -10.4% | -15.6 pts | SEC Filing (0001104659-19-040664) ↗ |
| Q1 2019 | Mar 31, 2019 | -6.1% | -19.1 pts | SEC Filing (0001104659-19-021809) ↗ |
| Q4 2018 | Dec 31, 2018 | -6.7% | – | SEC Filing (0001104659-19-002848) ↗ |
| Q3 2018 | Sep 30, 2018 | -5.5% | – | SEC Filing (0001104659-18-062380) ↗ |
| Q2 2018 | Jun 30, 2018 | 5.2% | – | SEC Filing (0001104659-18-045642) ↗ |
| Q1 2018 | Mar 31, 2018 | 13.0% | – | SEC Filing (0001104659-18-024701) ↗ |
Cite this data
StockData. (2026). Abbott Laboratories Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) International — Reported Sales Growth (%) (%), quarterly Q1 2018–Q3 2026 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/md-nm-yoy-rep-intl
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.